scispace - formally typeset
J

Joshua M. Farber

Researcher at National Institutes of Health

Publications -  107
Citations -  14702

Joshua M. Farber is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Chemokine & Chemokine receptor. The author has an hindex of 55, co-authored 99 publications receiving 14016 citations.

Papers
More filters
Journal ArticleDOI

CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and Disease

TL;DR: In this paper, the chemokine receptors CXCR4 and CCR5, members of the G protein-coupled receptor superfamily, have been identified as the principal coreceptors for T cell line-tropic and macrophagetropic HIV-1 isolates, respectively.
Journal ArticleDOI

Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2

TL;DR: It is demonstrated that murine β-defensin 2 (mDF2β) acts directly on immature dendritic cells as an endogenous ligand for Toll-like receptor 4 (TLR-4), inducing up-regulation of costimulatory molecules and d endritic cell maturation, suggesting that mDF2 β may play an important role in immunosurveillance against pathogens and, possibly, self antigens or tumor antigENS.
Journal ArticleDOI

Mig and IP-10: CXC chemokines that target lymphocytes

TL;DR: RHuMig and rIP‐10 share additional activities, including inhibition of neovascularization, inhibition of hematopoietic progenitor cells, and anti‐tumor effects, and that, despite their similar activities assayed in vitro, Mig and IP‐10/Crg‐2 may serve non‐redundant functions in vivo.

Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis In Vivo By Anne L. Angiolillo,* Cecilia Sgadari,~ Dennis D. Taub, S

TL;DR: In this article, the authors reported that IP-10 is a potent inhibitor of angiogenesis in vivo and showed that it significantly inhibited basic fibroblast growth factor-induced neovascularization of Matrigel.